Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare name with strong near-term evidence: Q1 2026 raised full-year guidance, Unity Confirm launch, peer-reviewed Northstar Response support, new oncology CMO, Q1 revenue of $108.4M, gross margin near 73%, positive free cash flow, and shares up about 19% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Improving margins ⢠High valuation BLLN has strong liquidity and improving margins, but weak historical returns, accumulated losses, financing reliance, and extreme valuation multiples make the shares high risk.
Price Behavior
Key Price Behavior Insights: ⢠Above average ⢠Volatile recovery ⢠Breakout resistance Support Level: $90.67 (secondary $88.00) Resistance Level: $99.00â$100.00 BLLN is modestly bullish over the last month above its ~$95 average, but volatile swings and $99â100 resistance warrant caution until a sustained breakout.
Sentiment & News
Key News Insights: ⢠Product expansion ⢠Clinical validation ⢠Margin compression BillionToOne's product advances and clinical validation support growth prospects, but margin pressure and slower sequential growth create near-term risk.
AI Summary
BLLN has shifted into a commercially scaling, cash-generative diagnostics platform with ample liquidity, but its premium valuation requires sustained test-volume growth and reimbursement-supported pricing; investors should wait for evidence that oncology adoption offsets recent ASP and margin pressure before underwriting further upside.
Description
BillionToOne, Inc. is a precision diagnostics company that quantifies DNA at single-molecule resolution to support molecular diagnostic applications. Its platform underlies a non-invasive prenatal screen that evaluates fetal chromosomal and genetic risks from maternal blood and a suite of liquid biopsy tests for tumor mutation profiling and methylation-based monitoring of cancer burden. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 23 | Jul 30 | BLLN | BillionToOne, Inc. | Healthcare name with strong near-term evidence: Q1 2026 raised full-year guidance, Unity Confirm launch, peer-reviewed Northstar Response support, new oncology CMO, Q1 revenue of $108.4M, gross margin near 73%, positive free cash flow, and shares up about 19% over 21 trading days. | Closed | +8.3% |
| Jul 16 | Jul 23 | BLLN | BillionToOne, Inc. | Healthcare momentum/catalyst name: stock up about 28% over 21 trading days, supported by Q1 results and guidance raise, a new prenatal product launch, peer-reviewed clinical study support, improving margins, strong liquidity, and positive free cash flow. | Closed | +0.6% |
| Jul 9 | Jul 16 | BLLN | BillionToOne, Inc. | Strong short-term setup with shares up about 22.8% over 21 trading days, a new 21-day high, and price well above its short-term average. Recent catalysts include Unity Confirm launch, raised full-year 2026 guidance, and peer-reviewed Northstar Response data outperforming standard imaging as an immunotherapy outcome predictor, alongside much-improved Q1 margins and strong liquidity. | Closed | +0.2% |
| Jul 1 | Jul 8 | BLLN | BillionToOne, Inc. | Strong momentum with supportive catalysts: stock rose about 31% over 21 trading days to a fresh closing high on 2026-07-01, while Q1 2026 raised full-year guidance, Unity Confirm launched, Northstar Response received peer-reviewed clinical validation, and liquidity remains strong. | Closed | -1.4% |
| Jun 23 | Jun 30 | BLLN | BillionToOne, Inc. | Positive catalyst stack includes Q1 2026 results and raised full-year guidance on 2026-05-06, the Unity Confirm launch on 2026-05-01, analyst upside commentary, and a 22% 21-day gain with improved margins in the latest quarter. | Closed | +15.1% |
| Jun 11 | Jun 18 | BLLN | BillionToOne, Inc. | Constructive healthcare momentum with recent catalysts: launched Unity Confirm on 2026-05-01, reported Q1 2026 results and raised full-year guidance on 2026-05-06, and has conference participation support. Shares are up about 11% over 21 trading days and remain above the 21-day average. | Closed | +5.5% |
| Nov 25 | Dec 2 | BLLN | BillionToOne, Inc. | BillionToOne (BLLN) is a hot IPO momentum candidate, with an 11% post-IPO rally, strong cash position, improving earnings metrics, and robust technical breakout above moving averages and upper Bollinger Band, although near-term overbought conditions suggest cautious positioning. | Closed | -11.5% |